Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Cady

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Headache|January 18, 2006
Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled studyStewart J Tepper, Roger Cady, David Dodick, et al.
BMC Neurology|July 4, 2024
Headache/migraine-related stigma, quality of life, disability, and most bothersome symptom in adults with current versus previous high-frequency headache/migraine and medication overuse: results of the Migraine Report Card surveyDawn C Buse, Roger Cady, Amaal J Starling, et al.
Clinical Therapeutics|April 5, 2021
Corrigendum to "Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study" [Clin Therapeut 42 (12) (2020) 2254-2265]Timothy R Smith, Marina Janelidze, George Chakhava, et al.
Headache|November 17, 2007
Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat A Migraine Early) studiesVincent Martin, Roger Cady, Alexander Mauskop, et al.
Cephalalgia : an International Journal of Headache|June 26, 2019
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trialDavid W Dodick, Richard B Lipton, Stephen Silberstein, et al.
Headache|September 28, 2004
Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studiesW Hester Visser, Paul Winner, Kim Strohmaier, et al.
Clinical Therapeutics|November 30, 2020
Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 StudyTimothy R Smith, Marina Janelidze, George Chakhava, et al.
Cephalalgia : an International Journal of Headache|February 21, 2020
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)Messoud Ashina, Joel Saper, Roger Cady, et al.
JAMA|June 15, 2021
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical TrialPaul K Winner, Peter McAllister, George Chakhava, et al.
The Journal of Headache and Pain|September 6, 2022
Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 studyRobert P Cowan, Michael J Marmura, Hans-Christoph Diener, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Headache|January 18, 2006
Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled studyStewart J Tepper, Roger Cady, David Dodick, et al.
BMC Neurology|July 4, 2024
Headache/migraine-related stigma, quality of life, disability, and most bothersome symptom in adults with current versus previous high-frequency headache/migraine and medication overuse: results of the Migraine Report Card surveyDawn C Buse, Roger Cady, Amaal J Starling, et al.
Clinical Therapeutics|April 5, 2021
Corrigendum to "Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study" [Clin Therapeut 42 (12) (2020) 2254-2265]Timothy R Smith, Marina Janelidze, George Chakhava, et al.
Headache|November 17, 2007
Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat A Migraine Early) studiesVincent Martin, Roger Cady, Alexander Mauskop, et al.
Cephalalgia : an International Journal of Headache|June 26, 2019
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trialDavid W Dodick, Richard B Lipton, Stephen Silberstein, et al.
Headache|September 28, 2004
Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studiesW Hester Visser, Paul Winner, Kim Strohmaier, et al.
Clinical Therapeutics|November 30, 2020
Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 StudyTimothy R Smith, Marina Janelidze, George Chakhava, et al.
Cephalalgia : an International Journal of Headache|February 21, 2020
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)Messoud Ashina, Joel Saper, Roger Cady, et al.
JAMA|June 15, 2021
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical TrialPaul K Winner, Peter McAllister, George Chakhava, et al.
The Journal of Headache and Pain|September 6, 2022
Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 studyRobert P Cowan, Michael J Marmura, Hans-Christoph Diener, et al.
Pageof 10